Current understanding of the impact of coronavirus disease-2019 (COVID-19) on
arrhythmias continues to evolve as new data emerge. Cardiac arrhythmias are more …

Aims Worldwide observational studies are evidencing discordance between guidelines and
realworld practice regarding direct oral anticoagulant drug (DOAC) doses. This systematic …

The “Guidelines on the Management of Valvular Heart Disease” were initially published as
the “Guidelines on Non-pharmacological Treatment of Valvular Heart Disease” in 2002 …

The American College of Cardiology (ACC) has a long history of developing documents (eg,
decision pathways, health policy statements, appropriate use criteria) to provide members …

Background Idarucizumab is a monoclonal antibody fragment with high affinity for
dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute …

Background Current guidelines consider vitamin K antagonists (VKA) the oral anticoagulant
agents of choice in adults with atrial arrhythmias (AA) and moderate or complex forms of …

Aims To assess the association between concurrent use of potential pharmacokinetic or
pharmacodynamic interacting drugs and major bleeding among direct oral anticoagulant …

Background and Purpose: The comparative effectiveness of direct-acting oral
anticoagulants, compared with warfarin, for risks of stroke/systemic embolism, major …

Importance Direct oral anticoagulants (DOACs) are purported to have fewer drug-drug
interactions than warfarin. However, potential interactions with coprescribed medications are …

Background: Patients with atrial fibrillation and severely decreased kidney function were
excluded from the pivotal non–vitamin K antagonist oral anticoagulants (NOAC) trials …